Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page

Q1-2023 Ophthalmology Update

Skip to the end of the Expertise Menu

Q1-2023 Ophthalmology Update

The ophthalmology sector experienced a slight slowdown in deal activity in the first quarter of 2022. Tight lending markets and more expensive debt has led to a more targeted M&A approach for most strategics buyers in the space, as they focus on opportunities where there is significant value creation and synergy potential. While we’ve observed much more variability in valuations industry-wide, practices with scale continue to attract premium multiples and seller-friendly business terms. Provident expects market conditions to persist for the next few months and improve in the second half of the year as debt markets settle down. We’re expecting many PE-backed platforms that have paused their own processes to relaunch in the back half of the year, which will drive significant M&A activity in the third and fourth quarter.

To print and download the full Ophthalmology Update report, please click below…

[holo_button icon=”/wp-content/uploads/2023/04/Q1-2023-Ophthalmology-Newsletter.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]